

REVIEW OF DECISIONS

BOARD MEETING

6-7 June 2024, Geneva, Switzerland

Decision 1: Consent Agenda: Board Committee Chair Appointment

The Gavi Alliance Board:

- a) **Appointed David Sidwell** as an Unaffiliated Board Member in the seat currently held by Naguib Kheraj, effective 1 August 2024 and until 31 July 2027; and
- b) **Appointed** the following as Chair of the Audit and Finance Committee effective 1 August 2024:
 - **David Sidwell** (Board Member) until 31 December 2025

Decision 2: Consent Agenda: Board and Committee Appointments

The Gavi Alliance Board:

- a) **Reappointed** **Awa-Marie Coll-Seck** as an Unaffiliated Board Member, effective 1 July 2024 and until 30 June 2027
- b) **Appointed** the following to the Audit and Finance Committee effective immediately:
 - **Karen Sorensen** (Board Member) until 31 December 2025
- c) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 August 2024:
 - **David Sidwell** (Board Member) until 31 December 2025
- d) **Appointed** the following to the Investment Committee effective immediately:
 - **David Sidwell** (Board Member) until 31 December 2025
 - **Karen Sorensen** (Board Member) until 31 December 2025
- e) **Reappointed** the following to the Programme and Policy Committee effective 1 July 2024:
 - **Awa-Marie Coll-Seck** (Board Member) until 31 December 2025
- f) **Appointed** the following to the Evaluation Advisory Committee effective immediately:
 - **Onei Uetela** (Alternate Board Member) until 31 December 2025

Decision 3: Consent Agenda: Appointment of Treasurer

The Gavi Alliance Board:

Appointed Francois Note as Treasurer with individual signatory authority, effective 1 July 2024 and until his successor is appointed and qualified.

Decision 4: Consent Agenda: Restrictive Measures Compliance Policy

The Gavi Alliance Board:

Approved the Restrictive Measures Compliance Policy as set out in Annex A to Doc 01e.

Decision 5: Gavi 6.0 – The Alliance's Strategy 2026-2030

The Gavi Alliance Board:

Approved the framework for the Alliance strategy 2026-2030 ('strategy one-pager') attached as Annex A to Doc 05.

Decision 6: Financial Update, including forecast

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee reviewed the financial implications of the recommendations to be made to the Programme and Policy Committee and concluded that the recommendations relating to the current strategic period were already included in the previous Financial Forecast and could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy, and, where relevant, remain subject to AMC Donors approval for re-purposing of COVAX AMC funds;
- b) **Approved** the updated Financial Forecast for the Gavi 5.1 (2021-2025) Strategic Period of Qualifying Resources of US\$ 10.6 billion and Forecast Expenditure of US\$ 10.5 billion;
- c) **Approved** the updated Financial Forecast for the COVAX AMC and COVID-19 programme of Qualifying Resources of US\$ 12.8 billion and Forecast Expenditure of US\$ 11.0 billion, with a COVAX AMC retained balance of US\$ 1.8 billion noting that the financial forecast does not include future interest income from COVAX AMC funds not yet disbursed for 2024 and 2025 of US\$ 180 million and the African Vaccine Manufacturing Accelerator or the Day Zero Financing Facility for 2024 and 2025 of US\$ 88 million; and
- d) **Agreed** that the budgetary amounts approved by the Gavi Alliance Board in Decision 12 of the Board Meeting of 7-8 December 2022 for Secretariat Resources (including COVAX) for 2023 and separately for 2024, be treated as an overall Budget amount which may be utilised across 2023 and 2024.

Decision 7: Vaccine Investment Strategy 2024 – Investment Cases (1/4)

The Gavi Alliance Board recognised that this Vaccine Investment Strategy (VIS) is taking place in a different global health and fiscal landscape with significant pressures on health systems, vaccination schedules and changing epidemiology due to climate change and urbanisation.

As the menu of vaccines available across the lifecourse increases, countries may require technical support to strengthen decision-making capacities on vaccine prioritisation and optimisation and support to strengthen their health systems to deliver them.

The Board also recognised the importance of the VIS for long-term market signalling to manufacturers despite the many unknowns.

Decision 7: Vaccine Investment Strategy 2024 – Investment Cases (2/4)

Considering this, the Gavi Alliance Board, subject to the availability of funding for the 2026-2030 period following Gavi's replenishment for that period:

- a) **Approved** in principle, support for a **tuberculosis (TB) vaccine programme**, contingent on the availability of a licensed product for adults/adolescents, outcomes of regulatory and technical review processes (including WHO prequalification and SAGE recommendation), and meeting the financial assumptions used as the basis for the TB investment case set out in Annex B to Doc 09;
- b) **Approved** in principle, support for a **dengue vaccine programme**, contingent on outcomes of regulatory and technical review processes and the availability and application of disease burden data in Gavi supported countries to inform the design of a vaccine programme, and meeting the financial assumptions used as the basis for the dengue investment case set out in Annex B to Doc 09;
- c) **Approved** in principle, support for a **group B streptococcus vaccine programme**, contingent on the availability of a licensed product, outcomes of regulatory and technical review processes (including WHO prequalification and SAGE recommendation), and meeting the financial assumptions used as the basis for the GBS investment case set out in Annex B to Doc 09;
- d) **Noted** continued exploration by the Secretariat of the need for, and design of, timely **market shaping interventions** aimed at ensuring that **TB vaccine supply** matches anticipated demand with minimal lag;

Decision 7: Vaccine Investment Strategy 2024 – Investment Cases (3/4)

- e) **Noted** the expected public health impact of a future **shigella** vaccine programme in Gavi-supported countries and that continued vaccine development is important, and **requested** the Secretariat to revert to the PPC with an updated investment case for a shigella vaccine programme when there is further information on country product preferences and timelines for technical guidance, policy and regulatory review processes;
- f) **Approved** the VIS learning agendas for 2026-2030 for **shigella, group B streptococcus, dengue and tuberculosis** as described in Annex B to Doc 09;
- g) **Approved** in principle, support for a **global stockpile of hepatitis E vaccines**, contingent on outcomes of regulatory and technical review processes (WHO prequalification), and meeting the financial assumptions used as the basis for the hepatitis E investment case set out in Annex B to Doc 09;
- h) **Approved** in principle, support for a **global stockpile of mpox vaccines**, contingent on outcomes of regulatory and technical review processes, and meeting the financial assumptions used as the basis for the mpox investment case set out in Annex B to Doc 09;
- i) **Noted** the financial implications associated with the above approvals (taken as a whole) for **2026-2030** are expected to be approximately US\$ 56.7 million, comprised of approximately US\$ 32.9 million for vaccine and operational cost support and approximately US\$ 23.8 million for learning agenda and reporting activities;
- j) **Noted** that the **routine COVID-19 programme will be discontinued** following the completion of the current 2024-2025 programme, and that support for COVID-19 in the event of a worst-case scenario would be considered through Gavi's pandemic preparedness, prevention and response activities;

Decision 7: Vaccine Investment Strategy 2024 – Investment Cases (4/4)

- k) **Approved** the VIS learning agendas starting from **2024** for **hepatitis E** and **mpox** vaccines, as described in Annex B to Doc 09 and **noted** that the financial implications associated with the above approvals for **2024-2025** are expected to be approximately US\$ 0.5 million, which the Secretariat will seek to absorb from the Board-approved budget for the 2021-2025 Strategic Period; and
- l) **Approved** from 2024, an appropriate role for the Gavi Alliance in responding to the ongoing mpox outbreak, including coordinating mpox dose donations in response to the ongoing outbreak in the Democratic Republic of the Congo and further potential outbreaks in surrounding countries. Building on lessons learnt from the COVAX Facility, this coordination role will be contingent upon favorable conditions, including the availability of resources, clear demand from countries, regulatory compliance, and reaching agreements that are actionable by all parties involved.

Decision 8a: Day Zero Financing Facility for Pandemics: First Response Fund

The Gavi Alliance Board:

Approved the specifications of the programmatic design of the First Response Fund of the Day Zero Financing Facility for Pandemics, including the Fund's programmatic parameters and eligibility criteria, as set out in Annex A to Doc 11.

Decision 8b: Day Zero Financing Facility for Pandemics: First Response Fund

The Gavi Alliance Board:

- a) **Approved** the Gavi Secretariat as interim treasury manager of the Day Zero Financing Facility – First Response Fund until 31 December 2024;
- b) **Noted** that the delegation of authority for release of funds will follow the existing Board-approved Delegation of Authority (DOA) Policy; and
- c) **Noted** that the Secretariat will recommend a long-term treasury management arrangement for the Fund and a proposal on the use of interest income to the AFC in the second half of 2024.

Decision 9a: African Vaccine Manufacturing Accelerator (AVMA)

The Gavi Alliance Board:

- a) **Approved** the amendments to the key terms of the African Vaccine Manufacturing Accelerator (AVMA) as set out in Annex A to Doc 12;
- b) **Noted** the AVMA Monitoring, Evaluation & Learning (MEL) Framework, including proposals for periodic course correction as set out in Annex B to Doc 12; and
- c) **Noted** the Key dependencies as set out in Annex C to Doc 12.

Decision 9b: African Vaccine Manufacturing Accelerator (AVMA)

The Gavi Alliance Board:

- a) **Approved** the Gavi Secretariat as interim treasury manager of the African Vaccine Manufacturing Accelerator (AVMA) until 31 December 2024; and
- b) **Noted** that the Gavi Secretariat will recommend a long-term treasury management arrangement for AVMA and make a proposal on the use of interest income to the AFC, in the second half of 2024.

Thank you